Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
57.89(c) 53.11(c) 50.16(c) 43.68(c) 42.23(c) Last
656 622 2 295 093 1 533 102 1 839 781 2 109 909 Volume
+2.33% -8.26% -5.55% -12.92% -3.32% Change
More quotes
Financials (USD)
Sales 2021 151 M - -
Net income 2021 -244 M - -
Net cash position 2021 303 M - -
P/E ratio 2021 -23,6x
Yield 2021 -
Sales 2022 220 M - -
Net income 2022 -238 M - -
Net cash position 2022 204 M - -
P/E ratio 2022 -25,3x
Yield 2022 -
Capitalization 5 879 M 5 879 M -
EV / Sales 2021 37,0x
EV / Sales 2022 25,8x
Nbr of Employees 622
Free-Float 92,6%
More Financials
Company
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. 
More about the company
Notations Surperformance© of Adaptive Biotechnologies Corporation
Trading Rating : Investor Rating :
More Ratings
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
03/05ADAPTIVE BIOTECHNOLOGIESá : Gets FDA EUA for T-Detect to Confirm Recent or Prior..
DJ
03/05Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Dete..
GL
03/05ADAPTIVE BIOTECHNOLOGIES CORPá : Change in Directors or Principal Officers (form..
AQ
03/03ADAPTIVE BIOTECHNOLOGIESá : Goldman Sachs Downgrades Adaptive Biotechnologies to..
MT
03/02ADAPTIVE BIOTECHNOLOGIES CORPá : Regulation FD Disclosure, Other Events (form 8-..
AQ
02/26ADAPTIVE BIOTECHNOLOGIESá : Morgan Stanley Adjusts Price Target on Adaptive Biot..
MT
02/25ADAPTIVE BIOTECHNOLOGIESá : to Present at the Cowen 41st Annual Healthcare Confe..
AQ
02/24ADAPTIVE BIOTECHNOLOGIES : 4Q Earnings Snapshot
AQ
02/24ADAPTIVE BIOTECHNOLOGIESá : Fourth Quarter and FY 2020 Earning Conference Call
PU
02/24ADAPTIVE BIOTECHNOLOGIESá : Management's Discussion and Analysis of Financial Co..
AQ
02/24ADAPTIVE BIOTECHNOLOGIESá : Reports Mixed Q4 Results; Net Loss Misses Street Vie..
MT
02/24ADAPTIVE BIOTECHNOLOGIES CORPá : Results of Operations and Financial Condition, ..
AQ
02/24ADAPTIVE BIOTECHNOLOGIESá : Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Repor..
MT
02/24Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial ..
GL
02/24ADAPTIVE BIOTECHNOLOGIESá : Launches T-Detect COVID, First Clinical T-Cell Based..
AQ
More news
News in other languages on ADAPTIVE BIOTECHNOLOGIES CORPORATION
2020ADAPTIVE BIOTECHNOLOGIES CORPORATION : Veröffentlichung des Quartalsergebnisses
2020ADAPTIVE BIOTECHNOLOGIES CORPORATION : publication des résultats trimestriels
2020ADAPTIVE BIOTECHNOLOGIES CORPORATION : Veröffentlichung des Halbjahresergebnisse..
2020ADAPTIVE BIOTECHNOLOGIES CORPORATION : publication des résultats semestriels
More news
Analyst Recommendations on ADAPTIVE BIOTECHNOLOGIES CORPORATION
More recommendations
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 67,33 $
Last Close Price 42,23 $
Spread / Highest target 75,2%
Spread / Average Target 59,4%
Spread / Lowest Target 42,1%
EPS Revisions
Managers and Directors
NameTitle
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Chad M. Cohen CFO, Principal Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Lance Baldo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION-28.58%5 879
EXACT SCIENCES CORPORATION-4.47%20 568
GUARDANT HEALTH, INC.3.31%13 585
BGI GENOMICS CO., LTD.1.61%8 244
INVITAE CORPORATION-18.34%6 714
IOVANCE BIOTHERAPEUTICS, INC.-31.53%4 756